The costly failure of amyloid-beta drugs: A cautionary tale in pharmaceutical development
2.8k words, 12 minute reading time
Read the full articleYou might also wanna read
New setback for the arrival of the first Alzheimer's drugs in the State
For a year now, Europe has had two approved drugs to slow the progression of Alzheimer's, but Catalan patients have not yet been able to ben
New setback for the arrival of the first Alzheimer's drugs in the State
For a year now, Europe has had two approved drugs to slow the progression of Alzheimer's, but Catalan patients have not yet been able to ben
The Amyloid Hypothesis for Alzheimer's disease and Aducanumab
Dr. Erik Musiek discusses the amyloid hypothesis and the challenges clinicians face in navigating discussions on the use of aducanumab for A
A Path to Preventing Cognitive Impairment Due to Alzheimer's Disease
Dr. Greg Cooper and Dr. Eric Reiman discuss emerging antibody therapies for preclinical Alzheimer's disease and the clinical, regulatory, an
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering The post An
Cost-Effectiveness of Aducanumab
Dr. Brian Callaghan discusses the AAN's comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug f
Experimental drug takes a new aim at Alzheimer’s, with promising early results
For years, scientists have struggled to crack one of Alzheimer’s biggest mysteries. That may finally be changing.
Comments
Sign in to join the conversation.
No comments yet. Be the first.